Imatinib Meta-methyl-piperazine Impurity

• CAT Number: R046728
• CAS Number: 1246819-59-9
• Molecular Formula: C29H31N7O
• Molecular Weight: 493.615
• Purity: ≥95%
• Synonyms: 3-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[(4-pyridinyl)-2-pyrimidinylamino]phenyl]benzamide
• Storage: -20°C
• IUPAC Name: 3-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
• InChI: InChI=1S/C29H31N7O/c1-21-8-9-25(18-27(21)34-29-31-12-10-26(33-29)24-7-4-11-30-19-24)32-28(37)23-6-3-5-22(17-23)20-36-15-13-35(2)14-16-36/h3-12,17-19H,13-16,20H2,1-2H3,(H,32,37)(H,31,33,34)
• InChIKey: HIPOQAXTOUMJRW-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5

The imatinib meta-methyl-piperazine impurity is a chemical byproduct typically formed during the synthesis of imatinib, a tyrosine kinase inhibitor used to treat certain cancers. This impurity may arise due to side reactions or incomplete purification processes. Characterization and quantification of this impurity are essential for ensuring the quality and safety of imatinib pharmaceutical formulations. Research focuses on developing methods to detect, quantify, and remove this impurity to meet regulatory standards and ensure the efficacy of imatinib medications.